The patients

Suffering from physical injuries, diabetes, cancer, autoimmune disease, central nervous system disorders, alcoholism, special populations- women and elderly.

 

The available treatments

Address the symptoms without targeting the root cause and are associated with serious side effects and often addiction.

​​

The clinical and economic burden

Is significant. Negatively impacting the daily functioning and quality of life of patients, their families, employers and healthcare system.

​​

The global Neuropathic Pain market

Is estimated to reach around US$ 25 Billion by the end of 2027.